Skip to content

Why are there several vaccines against COVID-19, but yet none against AIDS?

Dortmund, 14th June 2022

Portrait von Prof. Dr. Matthias Gunzer.

Prof Dr Matthias Gunzer heads the department of Biospectroscopy at ISAS and is Director of the Institute for Experimental Immunology and Imaging/Imaging Centre at Essen University Hospital.

© ISAS

Answer by Prof Dr Matthias Gunzer:

"First of all, one has to say that we in the western world are very lucky to only have to speak of HIV, the human immunodeficiency virus, and not of AIDS. The reason for this is our access to excellent medical care with so-called highly active antiretroviral therapies (HAART). These medications ensure that HIV-positive patients do not develop acquired immunodeficiency syndrome (AIDS). Unfortunately, the situation for those affected by HIV in other countries, such as in large parts of Africa, is worse. That is why we definetely need a vaccine in order to protect them from HIV.

Vaccination is the process of confronting the body with specific antigens; in the case of viral diseases such as COVID-19 or AIDS, these are components of the virus that causes the disease. The aim is for our body to produce antibodies and defence cells against the antigens. The result of a successful vaccination is then a protective immune response that can last for months or years.

Scientists have been researching HIV vaccines for decades. But of more than 400 clinical studies on possible vaccines that have taken place since 1987, none has been convincing in terms of the final result. However, this is by no means because too little research is being done on HIV. We can clearly see this in the successful treatment options that now exist, such as HAART. We should not forget that many years of research on HIV have also led to the fact that we now know a great deal about how antibodies work, for example – or about how to induce them particularly efficiently with a vaccine.

Compared to the coronavirus, however, the HI virus is incredibly variable: tens of thousands of new copies are created every day - in a single person. On average, each of these new copies carries at least one unique mutation. Therefore, over the years, a single person carries countless variants in their body, but only a few of these variants can be transmitted to others. The main problem that these variants pose for vaccines is that some mutations are located precisely in the parts of the virus that are usually attacked by the immune system. Therefore, mutations like these can help the virus remain unrecognised. A successful vaccine needs to elicit an immune response that can deal with this diversity in order to provide full protection against an infection.

In addition, unlike SARS-CoV-2, the HI virus is a true concealment artist. Parts of its surface are covered with a dense layer of sugar molecules - the glycan shield. This shield covers possible points of attack for antibodies. Although the coronavirus has such a sugar layer as well, the crucial areas of its spike protein remain uncovered. Thus, in the case of SARS-CoV-2, antibodies can recognise its spike protein and bind to it, thus neutralising the virus. The second hiding tactic that the HI virus uses is also tricky: the HI virus inserts its genetic blueprint into the DNA of its host, i.e. humans, and thus creates a hidden reservoir in the immune cells. This makes the HI viruses invisible to the immune system.

At present, six phase III trials are being conducted to investigate the efficacy and safety of potential HIV vaccines in large patient populations. Among the vaccine candidates are new variants such as those designed to elicit broadly neutralising antibodies and several based on mRNA molecules. Many people are already familiar with the latter because of the highly effective vaccines against COVID-19. That said, the research on HIV is ongoing - which is why, despite the challenges, we should by no means give up hope for an HIV vaccine."

(June 14, 2022)

Share

Further articles

8th September 2025

3 Questions for Susmita Ghosh

How does gut microbiota affect the immune system? Susmita Ghosh conducts research on proteins and immune cells at ISAS. In this interview, the biologist talks about her work and explains how gut flora and the immune system could affect the outcomes of a stroke.

Susmita Ghosh sitzt am ultrasensitiven Massenspektrometer und stellt eine Proben ein.
8th September 2025

Gut Flora & Stroke: How Microorganisms Influence Our Immune System

Which factors can activate immune cells after a stroke? This question was investigated by researchers at University Hospital Essen and ISAS. Their work focused on the gut microbiota.

23rd July 2025

3 Questions for Dr Ali Ata Tuz

In his doctorate, Dr Ali Ata Tuz researched the causes of immunodeficiency after strokes and was already working closely with ISAS at the time. Following this, he subsequently devoted himself to the behaviour of immune cells in the bioimaging research group at ISAS. In this interview, the physician talks about his path from the clinic to application-oriented basic research.

Dr. Ali Ata Tuz sitzt am Konfokalmikroskop und schaut frontal in die Kamera.. Auf dem Bildschirm nebem dem Mirkoskop sind in grün und violett Mikroskopaufnahmen von einer Probe im Mikroskop zu sehen.
8th July 2025

Heart Failure Rarely Occurs on Its Own: ISAS Researchers Develop New Treatment Pillars

The symptoms, subsequent problems and therapeutic challenges of patients with heart failure are increasingly challenging for general practitioners and cardiologists. Doctors are limited in their choice of treatment options, especially for patients with additional diseases. At ISAS, researchers are therefore focussing on broadening the therapeutic spectrum.

Prof. Dr. Kristina Lorenz.
25th June 2025

New Ionisation Method: From Open Questions to Closed Plasma

Mass spectrometry only works with electrically charged, i.e. ionised, particles. Researchers often use plasma for this purpose. In a series of publications, scientists from the Miniaturisation Research Group have shed new light on this ionisation method and presented a completely new type of plasma. This does not require a continuous gas flow and is therefore particularly resource-efficient.

Cayian Tian adjusts the gas supply to the plasma.
11th June 2025

“We essentially ask ourselves the same questions”

In the ISAS cooperation project “The Secret World of the Immune System”, ISAS researchers and artists from the storyLab kiU at Dortmund University of Applied Sciences and Arts brought microscope data to life in an immersive space. Lennart Oberscheidt, research associate and visual effects (VFX) supervisor at storyLab kiU, talks about the special features of the project and the similarities between art and research in an interview.

30th May 2025

What Can't Be Missing From Your Project, Laxmikanth Kollipara?

In many research projects, there is one thing that is essential for success. Perhaps a rare sample or a special device? For Dr Laxmikanth Kollipara, that one thing is a very special pillar from the PIPMet project.

Dr Laxmikanth Kollipara stands in the laboratory holding a silver-coloured column. In the background are HPLC systems.
14th May 2025

“Moving to ISAS changed my whole view on mass spectrometry”

Prof Dr Miloš Filipović is researching the connection between ageing processes and gasotransmitter signalling pathways, in particular hydrogen sulphide. The biochemist headed the ERC Sulfaging group at ISAS from October 2020 until February 2025, at which point he was appointed to the University of Glasgow in Scotland. In this interview, he looks back on the past four and a half years in Dortmund and talks about his experiences at ISAS.

Dr. habil. Milos Filipovic.
30th April 2025

Humboldt Fellow Prof Dr Xiaowei Xu started at ISAS in March

Prof Dr Xiaowei Xu from the Chinese Guangdong Cardiovascular Institute is researching the clinical application of artificial intelligence (AI) in the context of cardiovascular diseases. For 18 months in total, he will be researching various AI methods for analysing cell images as a Humboldt Fellow at ISAS.

Prof Dr Xiaowei Xu in front of the ISAS city building.